Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Ascendis Health's accounts receivables for the quarter that ended in Jun. 2023 was R224 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Ascendis Health's Days Sales Outstanding for the quarter that ended in Jun. 2023 was 53.99.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Ascendis Health's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was R0.08.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Ascendis Health's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Ascendis Health's accounts receivable are only considered to be worth 75% of book value:
Ascendis Health's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Ascendis Health Accounts Receivable Related Terms
Ascendis Health Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Ascendis Health's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascendis Health (JSE:ASC) has a Accounts Receivable of R224 Mil as of Jun. 2023. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Ascendis Health and its competitors.
Is Ascendis Health's Accounts Receivable too high?
Ascendis Health's current Accounts Receivable is R224 Mil. Overall, Ascendis Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Health's Accounts Receivable compare to PHBI and GCAN?
Ascendis Health's Accounts Receivable of R224 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Distribution company?
A good Accounts Receivable depends on the Medical Distribution industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Ascendis Health and its competitors. Ascendis Health's current Accounts Receivable is R224 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Health stock overvalued right now?
Ascendis Health (JSE:ASC) has a current Accounts Receivable of R224 Mil. The current Accounts Receivable is R224 Mil. Ascendis Health's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Ascendis Health (JSE:ASC), the current Accounts Receivable is R224 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Health Ltd is a health and wellness investment holding Company that holds investments in a number of companies that market and distribute a portfolio of brands, products, and medical devices. The company operates in two segments: i) Consumer Health (wellness, health supplements, speciality ingredients and compounded medicines) and ii) Medical Devices (distributor of medical devices, in vitro diagnostic products and orthopaedic equipment). The company generates the majority of its revenue from the Medical Devices segment.
11GF Score
Get the complete analysis for JSE:ASC
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ASC has been successfully added to your 
